SPDR S&P Biotech (XBI)

Add to Watchlists
Create an Alert
233.65 +0.64  +0.27% NYSE Arca May 27, 10:02AM Delayed 2m USD
View Full Chart
XBI Price Chart

XBI Description

SPDR S&P Biotech is a long only equity fund managed by SPDR State Street Global Advisors that tracks the S&P Biotechnology Select Industry TR USD index and has 2.271B USD assets under management. It has an expected distribution yield of 0.82%, a Forecasted PE Ratio of 28.58, and a Forecasted Price to Book Value of 5.152. The fund has a net expense ratio of 0.35%, turns over its positions 86.00% per year, and is traded on the New York Stock Exchange Arca.

XBI Key Info

Expense Ratio (2-3-15) 0.35%
Assets Under Management (5-26-15) 2.271B
30-Day Average Volume (5-26-15) 1.114M
Net Asset Value (5-22-15) 234.02
Discount or Premium to NAV (5-20-15) -0.05%
Turnover Ratio (6-30-14) 86.00%

XBI Asset Allocation

Type % Net % Long % Short
Cash 0.11% 0.11% 0.00%
Stock 99.89% 99.89% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of May 19, 2015

XBI Region Exposure

Americas 97.87%
North America 97.87%
Latin America 0.00%
Greater Europe 2.13%
United Kingdom 0.00%
Europe Developed 2.13%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.00%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.0%
% Emerging Markets 0.00%
As of May 22, 2015
Region breakdown data is calculated by using the long position holdings of the portfolio.

XBI Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of May 19, 2015

XBI Stock Market Capitalization

Giant 4.20%
Large 5.24%
Medium 14.86%
Small 33.90%
Micro 41.69%
As of May 19, 2015
View More Holdings

XBI Top 10 Holdings

Name % Weight Price Chg %
Synageva BioPharma Corp 2.02% 214.26 +0.12%
Alder BioPharmaceuticals Inc 1.60% 41.20 +3.54%
Esperion Therapeutics Inc 1.58% 103.50 -0.24%
Dyax Corp 1.57% 26.35 +0.57%
Ultragenyx Pharmaceutical Inc 1.49% 83.72 +1.31%
bluebird bio Inc 1.45% 185.53 +1.00%
Repligen Corp 1.36% 41.00 +1.21%
Momenta Pharmaceuticals Inc 1.32% 19.49 +0.52%
Exelixis Inc 1.24% 3.16 +0.32%
Incyte Corp 1.24% 107.78 +0.46%
As of May 19, 2015
Advertisement

XBI Basic Info

Style
Broad Asset Class Sector Equity
Broad Category Equity
Prospectus Objective Specialty - Health
Fund Owner Firm Name SPDR State Street Global Advisors
Benchmark Index
S&P Biotechnology Select Industry TR USD 100.0%
Key Dates
Inception Date 1/31/2006
Last Annual Report Date 6/30/2014
Last Prospectus Date 2/3/2015
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan Yes
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available RRSP No

XBI Manager Info

Name Tenure
John Tucker 9.17 yrs
Karl Schneider 0.42 yrs
Michael Feehily 3.42 yrs

XBI Risk Info

Beta 1.103
30 Day Average Volatility 30.50%

XBI Fundamentals

Dividend Yield TTM (5-27-15) 0.82%
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio 12.13
Weighted Average Price to Book Ratio 6.809
Weighted Median ROE -17.02%
Weighted Median ROA -21.21%
Forecasted Dividend Yield 0.03%
Forecasted PE Ratio 28.58
Forecasted Price to Sales Ratio 4.861
Forecasted Price to Book Ratio 5.152
Number of Holdings 98
As of May 19, 2015

XBI Growth Estimates

Forecasted 5 Yr Earnings Growth 16.08%
Forecasted Book Value Growth 10.45%
Forecasted Cash Flow Growth 15.05%
Forecasted Earnings Growth 18.55%
Forecasted Revenue Growth 5.82%
As of May 19, 2015

XBI Performance

  Returns Total Returns
1M -0.09% -0.09%
3M 7.23% 7.34%
6M 29.44% 29.91%
1Y 81.45% 83.49%
3Y 184.1% 189.1%
5Y 341.4% 349.1%
As of May 22, 2015

XBI Flows

1M 100.65M
3M 177.34M
6M 427.47M
YTD 427.73M
1Y 436.43M
3Y 622.35M
5Y 477.24M
As of April 30, 2015
Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 7-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 7-Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.